Search Results

Suggested Topics within your search.
Refine Results
  1. 1
    Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity <i>in vitro</i> and in a model of psoriasis

    Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity <i>in vitro</i> and in a model of psoriasis by PH Schafer, Andrew Parton, Ajeet Kumar Gandhi, Lori Capone, Mary Beth Adams, Lei Wu, JB Bartlett, MA Loveland, Amos Gilhar, Y‐F Cheung, GS Baillie, Miles D. Houslay, H‐W Man, G. Müller, DI Stirling

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

    Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast by Melinda Gooderham, Kim Papp

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors

    Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors by Miguel Pérez‐Aso, M. Carmen Montesinos, Aránzazu Mediero, Tuere Wilder, Peter Schäfer, Bruce N. Cronstein

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and S... by Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis

    Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis by Alexander Nast, Anja Jacobs, Stefanie Rosumeck, Ricardo Niklas Werner

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    A Review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology

    A Review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology by Farah Moustafa, Steven R. Feldman

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

    The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Res... by Peter Schäfer, Peng Chen, Lorraine Fang, Andrew Wang, Rajesh Chopra

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast

    New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast by Andrew C. Palfreeman, McNamee, Fiona E. McCann

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases

    Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases by Miriam Wittmann, Philip Helliwell

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

    Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity by Peter Schäfer, Anastasia Parton, Lori Capone, Dorota Cedzik, Helen Brady, Jilly F. Evans, Hon‐Wah Man, George W. Muller, David Stirling, Rajesh Chopra

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

    Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study by Gülen Hatemi, Melike Melikoğlu, Recep Tunç, Cengiz Korkmaz, Banu Öztürk, Cem Mat, Peter A. Merkel, Kenneth Calamia, Ziqi Liu, Lilia Pineda, Randall M. Stevens, Hasan Yazıcı, Yusuf Yazıcı

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

    Can the anti‐inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? by M A Giembycz

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

    Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis surve... by P.C.M. van de Kerkhof, Kristian Reich, Arthur Kavanaugh, H. Bachelez, Juliet N. Barker, Giampiero Girolomoni, Richard Langley, C. Paul, L. Puig, Mark Lebwohl

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Advances in treating psoriasis

    Advances in treating psoriasis by Katharina Belge, Jürgen Brück, Kamran Ghoreschi

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study

    Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study by Vibeke Strand, Georg Schett, ChiaChi Hu, Randall M. Stevens

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Phosphodiesterase 4-targeted treatments for autoimmune diseases

    Phosphodiesterase 4-targeted treatments for autoimmune diseases by Neal Kumar, Ari M. Goldminz, Noori Kim, Alice B. Gottlieb

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  17. 17
    Psoriatic arthritis therapy: NSAIDs and traditional DMARDs

    Psoriatic arthritis therapy: NSAIDs and traditional DMARDs by Peter Nash, Daniel O. Clegg

    Published 2005
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

    Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis by Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, Adewale O. Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Marla Hochfeld, Lichen L. Teng, Georg Schett, Éric Lespessailles, Stephen Hall

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

    Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled tri... by C. Paul, Jennifer Clay Cather, Melinda Gooderham, Yves Poulin, Ulrich Mrowietz, Carlos Montilla, J. Crowley, ChiaChi Hu, R.M. Stevens, Kara N. Shah, R. M. Day, Giampiero Girolomoni, A.B. Gottlieb

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

    Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases by Georg Schett, Victor S. Sloan, Randall M. Stevens, Peter Schäfer

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: